| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_7046f40e8f03883a036658203260e3f4 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P1-16
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-7028 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P1-16
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-7028 |
| filingDate |
2020-01-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_89c0cc8a1c59ee56620f1c7a332a1384
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_450d1fc4b2c6c1d85f446d3967d24635
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ca0424189ec8640766415cc2edee7ab5
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6b88ae1a90e6d52b70bd327a2a773b2e
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b50585da99312f73ba8fca9ff850de0e
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ce7204601bedf747d3aad30b8f51dfc5
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7ea671a69cf592dbd181893e1507b294
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_282d7bf43daeb8f5206969d96d4253a3
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1904772d2ad506abacf9bcca50d8be51 |
| publicationDate |
2020-04-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
CN-111012789-A |
| titleOfInvention |
Application of amygdalin in the preparation of medicaments for the treatment of fatty liver disease |
| abstract |
The invention relates to the application of amygdalin in the preparation of a medicine for treating fatty liver disease. Through the research of the inventor, it was found for the first time that amygdalin has a significant therapeutic effect on non-alcoholic fatty liver disease. It can significantly improve the abnormal biochemical indicators of liver injury, and significantly reduce liver lipid accumulation. The completed animal model test of the present invention shows that for the high-fat diet-induced mouse non-alcoholic steatohepatitis model or the methionine choline-deficient diet-induced mouse non-alcoholic steatohepatitis model, the use of amygdalin can be used for intervention. Significantly decreased serum aspartate aminotransferase and glutamate pyruvate aminotransferase levels, decreased liver tissue triglyceride content, improved liver histopathological changes, and inhibited liver lipid accumulation. The effect is significantly better than other test drugs. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-113679731-A |
| priorityDate |
2020-01-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |